Biocartis, Exploit Technologies Ink MDx Assay Development Deal

Jul 10, 2017

|

NEW YORK (GenomeWeb) – Biocartis announced today that it has extended its partnership with Exploit Technologies (ETPL) — the commercialization arm of Singapore's Agency for Science, Technology, and Research — to develop molecular diagnostic assays, including one for breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis, Exploit Technologies Ink MDx Assay Development Deal

To read the full story....

Breaking News

SphingoTec, BHR Pharmaceuticals Ink Dx Distribution Deal for UK, Ireland

Oxford Immunotec Gets FDA Clearance for TB Test in Patients Aged Two and Older

FDA Grants Emergency Use Authorization for Genetrack Biolabs SARS-CoV-2 Molecular Assay

US to Distribute 150 Million Abbott SARS-CoV-2 Antigen Tests at No Cost

Swift Biosciences, BillionToOne Partner to Commercialize COVID-19 Test

Inflammatix Receives $1.1M DARPA Award to Develop Predictive COVID-19 Diagnostic

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

Israeli Startup LessTests Uses Single-Step Pooling Software to Multiply COVID-19 Testing Capacity

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

Sponsorships